Deaths from cancer or infections can occur when available treatments are ineffective. Once turned on, the pregnane X receptor (PXR) activates the expression of genes encoding enzymes that metabolize external chemicals, including drugs. This causes a significant drop in the effectiveness of chemotherapy, antivirals, and other pharmaceuticals. Blocking the PXR activity is notoriously difficult, as many drugs that bind the protein, whether intentionally or unintentionally, activate it. Scientists at St. Jude Children’s Research Hospital have leveraged chemical and structural studies in the design of PXR inhibitors to better understand this process. The findings, published in Nature Communications, provide new insights into the relationship between compounds that activate PXR and ones that block its activity, with implications for designing more effective therapeutics. Removing toxic compounds from our bodies is a vital process to maintain overall health and well-being. To accomplish this, the human body has a toxin-removal system. A family of proteins called cytochrome P450 plays a significant role in this process; however, these proteins do not discriminate between toxins and well-intentioned therapeutics. Higher drug doses are often needed to overcome the work these proteins do to eliminate drugs and toxins alike from the body. Cytochrome P450 protein levels are elevated when a drug binds to and activates their respective regulators, such as nuclear receptors, which in turn activates cytochrome P450 genes’ expression. In particular, PXR regulates the expression of a central player in drug metabolism, CYP3A4. “PXR is a transcription factor that regulates the gene expression of CYP3A4, and when a drug binds to and activates PXR, it upregulates CYP3A4,” said corresponding author Taosheng Chen, PhD, St. Jude Department of Chemical Biology & Therapeutics. “CYP3A4 metabolizes more than half of drugs on the market, so it’s clear how important it is.” CYP3A4 inhibitors, such as ritonavir, have shown benefit when used in combination with the anti-SARS-CoV-2 drug Paxlovid by stopping its active ingredient, nirmatrelvir, from being metabolized by CYP3A4 too quickly. Directly inhibiting PXR activity represents an alternative solution to control drug metabolism by CYP3A4. If drug-metabolizing proteins like CYP3A4 are the hired goons, then PXR represents the mob boss. The researchers’ challenge was overcoming generations of PXR evolution, which has turned the protein into a juggernaut of ligand promiscuity. “Lots of compounds can bind to PXR,” explained Chen. “There are even very small compounds that by themselves, are inactive. But if you combine a few of them, they can bind to different areas of PXR and together activate it.” The flexibility that allows it to bind thousands of different compounds also means inhibiting its function requires a deft touch. Previous work from the Chen lab on PXR inhibitor discovery identified the inhibitor SPA70 as a potent candidate. But as a testament to PXR’s unique capabilities, very minor changes to SPA70 flipped it into an activator rather than an inhibitor. In this study, Chen and his team leveraged chemical and structural studies to understand the molecular basis behind the subtle differences between activator and inhibitor binding. To address these differences, the researchers used X-ray crystallography to obtain the first-ever atomic structures of PXR bound to an inhibitor, presenting four new PXR structures with different inhibitors bound. These could be used to compare old and new structures of PXR bound to activators with almost identical chemical structures to the inhibitors to pinpoint the exact protein regions that govern PXR activity. “The activator and inhibitor structures are very similar, except that the activators interact with a region of PXR we call activation function-2, AF2,” said Chen. “The inhibitor failed to interact effectively.” The AF2 region appeared to be crucial in determining whether a drug would function as an activator or inhibitor. “When you have an activator, the conformation of the AF2 is different from that induced by an inhibitor. And it would favor either co-activator or co-repressor recruitment, respectively,” explained Chen. “So, it’s almost like a gatekeeper.” Building on the information gained from these structures, the researchers found they could flip the drugs between activator and inhibitor by rationally adding or taking away pieces of the molecules based on the identified “hot spots” within the protein. Chen hopes these findings will spark new research into more effective PXR inhibitors, which could potentially be used to prevent PXR-mediated drug metabolism. Garcia-Maldonado E, Huber AD, Chai SC et al.Chemical manipulation of an activation/inhibition switch in the nuclear receptor PXR.

The Pharmaceuticals Export Promotion Council of India (Pharmexcil), in collaboration with the Embassy of India in Armenia, is aiming to fortify trade relations and tap into the burgeoning pharmaceutical market in Armenia. In order to initiate the collaboration, Pharmexcil is all set to host a webinar titled “Armenia-India Collaborative Opportunities in the Pharmaceutical Sector” on May 17, 2024. Armenia, a promising market within the Commonwealth of Independent States (CIS) region, imported pharmaceuticals worth USD 213.7 million in 2022. The market is projected to grow to USD 548.4 million by 2027, reflecting a compound annual growth rate (CAGR) of 10.4%. Scheduled to commence at 17:30 IST (16:00 Armenian Time), the webinar will offer in-depth insights into Armenia’s regulatory framework, enabling Indian pharmaceutical companies to better navigate and engage with the Armenian market. The webinar will feature experts from Armenia discussing regulatory aspects and recent healthcare reforms aimed at Universal Health Insurance. This will equip participants with critical knowledge to leverage opportunities in the expanding Armenian market. Uday Bhaskar, director general (DG) of Pharmexcil, emphasized the significance of this event, stating, “I urge member companies to take advantage of this opportunity to explore and expand their presence in the Armenian health sector. The insights gained from this webinar will be invaluable for enhancing our exports to Armenia.” A Q&A session will follow the presentations, allowing participants to interact directly with Armenian stakeholders, fostering potential business collaborations.